Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189150

SCHEMBL7189150

SCHEMBL7189150

COCCOc1ccc(PC(=O)c2c(C)cc(C)c(C)c2C)cc1.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.36
▸ ACACB O00763 1/20 0.36
▸ TDP1 Q9NUW8 2/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ ITGB1 P05556 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ITGA4 P13612 1/20 0.34
▸ CHEK1 O14757 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CHEK2 O96017 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ PPARG P37231 3/20 0.33
▸ PPARD Q03181 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ITGB3 P05106 1/20 0.33
▸ ITGAV P06756 1/20 0.33
▸ ITGA5 P08648 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182605 0.89 ITGB1 (0.42) ITGB1KDM4EITGA4SMN1; SMN2
SCHEMBL7182457 0.89 L3MBTL1 (0.42) MAPTL3MBTL1ITGB1KDM4EITGA4
SCHEMBL7187868 0.88 THRA (0.40) ACACBTDP1L3MBTL1MAPK14FFAR1
SCHEMBL7186832 0.87 ITGB1 (0.42) MAPTACACBTDP1L3MBTL1ITGB1
SCHEMBL7178277 0.86 ITGB1 (0.45) ITGB1ITGA4
SCHEMBL7190160 0.86 ALDH1A1 (0.39) TDP1
SCHEMBL7183843 0.85 KDM4E (0.38) MAPTACACBTDP1L3MBTL1KDM4E
SCHEMBL7187888 0.85 NR5A1 (0.47) ITGB1ITGA4
SCHEMBL7180869 0.85 MAPK1 (0.46) TDP1SMN1; SMN2RAB9A
SCHEMBL7186821 0.84 LMNA (0.37) L3MBTL1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885ACACB 914/4885TDP1 4234/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885ACACB 555/4885TDP1 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.